Announced details
The disclosure states that clinical trials have been conducted in several hundred patients in late-stage clinical studies, and that safety and efficacy have been demonstrated in several hundred patients across multiple indications.
The relationship with FIRM is through the members-only presentation. 株式会社Akatsuki Therapeutics is the Company's development partner.
The Forum for Innovative Regenerative Medicine (FIRM) is described as the organizer of the members-only presentation and as a membership organization. 株式会社Akatsuki Therapeutics is the Company's development partner and leads the development of eNK® cells. Other information, including its location, representative, capital and year of establishment, is not disclosed.
Pacifico Yokohama (trade show venue)
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Regenerative medicine and CDMO platform, HLCM051, Universal Donor Cell (UDC), eNK® cells (AKT-01/HLCN061) |
| Counterparty | Forum for Innovative Regenerative Medicine (FIRM), a general incorporated association, Akatsuki Therapeutics |
| Counterparty overview | The Forum for Innovative Regenerative Medicine (FIRM) is described as the organizer of the members-only presentation and as a membership organization. 株式会社Akatsuki Therapeutics is the Company's development partner and leads the development of eNK® cells. Other information, including its location, representative, capital and year of establishment, is not disclosed. |
| Relationship with the Company | The relationship with FIRM is through the members-only presentation. 株式会社Akatsuki Therapeutics is the Company's development partner. |
| Launch date | 7–9 October 2026 (scheduled exhibition and presentation dates) |
| Applicable area | Regenerative Medicine, Acute Respiratory Distress Syndrome (ARDS), Acute phase of cerebral infarction, Trauma-induced acute kidney injury (AKI), Cancer immunotherapy for solid tumors, Ophthalmology, Liver disease |
| Location | Pacifico Yokohama (trade show venue) |
| Usage history | The disclosure states that clinical trials have been conducted in several hundred patients in late-stage clinical studies, and that safety and efficacy have been demonstrated in several hundred patients across multiple indications. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To introduce its research and development initiatives in the regenerative medicine field through the exhibition and presentation, and to create opportunities for dialogue with potential partner companies and research institutions in Japan and overseas.